RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation
Highlights • Progression patterns at the RECIST-PD during treatment with EGFR-TKIs were clinically heterogeneous. • We evaluated the association between progression patterns and clinical outcome after treatment. • Progression patterns at the RECIST-PD during EGFR-TKI treatment might be associated wi...
Gespeichert in:
| Veröffentlicht in: | Lung cancer (Amsterdam, Netherlands) Netherlands), 2015-12, Vol.90 (3), p.477-483 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 483 |
|---|---|
| container_issue | 3 |
| container_start_page | 477 |
| container_title | Lung cancer (Amsterdam, Netherlands) |
| container_volume | 90 |
| creator | Yoshida, Tatsuya Yoh, Kiyotaka Niho, Seiji Umemura, Shigeki Matsumoto, Shingo Ohmatsu, Hironobu Ohe, Yuichiro Goto, Koichi |
| description | Highlights • Progression patterns at the RECIST-PD during treatment with EGFR-TKIs were clinically heterogeneous. • We evaluated the association between progression patterns and clinical outcome after treatment. • Progression patterns at the RECIST-PD during EGFR-TKI treatment might be associated with clinical outcome after treatment failure. |
| doi_str_mv | 10.1016/j.lungcan.2015.09.025 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1760917235</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169500215300696</els_id><sourcerecordid>1760917235</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-59035691d0bdcf56d2f9ab54cd25a65ff25f15849955eff8ae09efd0d30df8e03</originalsourceid><addsrcrecordid>eNqFUsFuEzEQXSEQDYVPAPnIZdOxN96sLyAUpaVSJaS2nC3HHqdOd-1geyvlR_q9eEng0AsX-zBv3pt5b6rqI4U5Bdpe7Ob96Lda-TkDyucg5sD4q2pGuyWru6Zhr6tZwYmaA7Cz6l1KOwC6pCDeVmesbWEBDZ1Vz7fr1fXdPdnHsI2Ykgue7FXOGH0iZozOb8n66vKW5EMMyXkkj86rhMT5B7dxOUSSI6o8oM8kWKLMk_IaDfHB12lQfU80lmcaluipFCd-V-CJPKi4CX8klD-qDGMuxeDfV2-s6hN-OP3n1c_L9f3qe33z4-p69e2m1gsGueYCGt4KamBjtOWtYVaoDV9ow7hqubWMW8q7hRCco7WdQhBoDZgGjO0QmvPq85G37P9rxJTl4NI0sPIYxiTpsgVBl6zhBcqPUF2MSBGt3Ec3qHiQFOQUidzJUyRyikSCkCWS0vfpJDFuBjT_uv5mUABfjwAsiz45jDLp4k8x0UXUWZrg_ivx5QWD7p13WvWPeMC0C2P0xUVJZWIS5N10F9NZUN4AtKJtfgM807dw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1760917235</pqid></control><display><type>article</type><title>RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Yoshida, Tatsuya ; Yoh, Kiyotaka ; Niho, Seiji ; Umemura, Shigeki ; Matsumoto, Shingo ; Ohmatsu, Hironobu ; Ohe, Yuichiro ; Goto, Koichi</creator><creatorcontrib>Yoshida, Tatsuya ; Yoh, Kiyotaka ; Niho, Seiji ; Umemura, Shigeki ; Matsumoto, Shingo ; Ohmatsu, Hironobu ; Ohe, Yuichiro ; Goto, Koichi</creatorcontrib><description>Highlights • Progression patterns at the RECIST-PD during treatment with EGFR-TKIs were clinically heterogeneous. • We evaluated the association between progression patterns and clinical outcome after treatment. • Progression patterns at the RECIST-PD during EGFR-TKI treatment might be associated with clinical outcome after treatment failure.</description><identifier>ISSN: 0169-5002</identifier><identifier>EISSN: 1872-8332</identifier><identifier>DOI: 10.1016/j.lungcan.2015.09.025</identifier><identifier>PMID: 26604031</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung - diagnosis ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - mortality ; Disease Progression ; EGFR tyrosine kinase inhibitors ; Epidermal growth factor receptor mutation ; Exons ; Female ; Hematology, Oncology and Palliative Medicine ; Humans ; Kaplan-Meier Estimate ; Lung Neoplasms - diagnosis ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Lung Neoplasms - mortality ; Male ; Middle Aged ; Mutation ; Neoplasm Staging ; Non-small cell lung cancer ; Protein Kinase Inhibitors - therapeutic use ; Pulmonary/Respiratory ; Quinazolines - therapeutic use ; Receptor, Epidermal Growth Factor - antagonists & inhibitors ; Receptor, Epidermal Growth Factor - genetics ; Response Evaluation Criteria in Solid Tumors ; Retrospective Studies ; Treatment Outcome</subject><ispartof>Lung cancer (Amsterdam, Netherlands), 2015-12, Vol.90 (3), p.477-483</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2015 Elsevier Ireland Ltd</rights><rights>Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-59035691d0bdcf56d2f9ab54cd25a65ff25f15849955eff8ae09efd0d30df8e03</citedby><cites>FETCH-LOGICAL-c420t-59035691d0bdcf56d2f9ab54cd25a65ff25f15849955eff8ae09efd0d30df8e03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.lungcan.2015.09.025$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26604031$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yoshida, Tatsuya</creatorcontrib><creatorcontrib>Yoh, Kiyotaka</creatorcontrib><creatorcontrib>Niho, Seiji</creatorcontrib><creatorcontrib>Umemura, Shigeki</creatorcontrib><creatorcontrib>Matsumoto, Shingo</creatorcontrib><creatorcontrib>Ohmatsu, Hironobu</creatorcontrib><creatorcontrib>Ohe, Yuichiro</creatorcontrib><creatorcontrib>Goto, Koichi</creatorcontrib><title>RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation</title><title>Lung cancer (Amsterdam, Netherlands)</title><addtitle>Lung Cancer</addtitle><description>Highlights • Progression patterns at the RECIST-PD during treatment with EGFR-TKIs were clinically heterogeneous. • We evaluated the association between progression patterns and clinical outcome after treatment. • Progression patterns at the RECIST-PD during EGFR-TKI treatment might be associated with clinical outcome after treatment failure.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Carcinoma, Non-Small-Cell Lung - diagnosis</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Disease Progression</subject><subject>EGFR tyrosine kinase inhibitors</subject><subject>Epidermal growth factor receptor mutation</subject><subject>Exons</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Lung Neoplasms - diagnosis</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - mortality</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Neoplasm Staging</subject><subject>Non-small cell lung cancer</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Pulmonary/Respiratory</subject><subject>Quinazolines - therapeutic use</subject><subject>Receptor, Epidermal Growth Factor - antagonists & inhibitors</subject><subject>Receptor, Epidermal Growth Factor - genetics</subject><subject>Response Evaluation Criteria in Solid Tumors</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><issn>0169-5002</issn><issn>1872-8332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUsFuEzEQXSEQDYVPAPnIZdOxN96sLyAUpaVSJaS2nC3HHqdOd-1geyvlR_q9eEng0AsX-zBv3pt5b6rqI4U5Bdpe7Ob96Lda-TkDyucg5sD4q2pGuyWru6Zhr6tZwYmaA7Cz6l1KOwC6pCDeVmesbWEBDZ1Vz7fr1fXdPdnHsI2Ykgue7FXOGH0iZozOb8n66vKW5EMMyXkkj86rhMT5B7dxOUSSI6o8oM8kWKLMk_IaDfHB12lQfU80lmcaluipFCd-V-CJPKi4CX8klD-qDGMuxeDfV2-s6hN-OP3n1c_L9f3qe33z4-p69e2m1gsGueYCGt4KamBjtOWtYVaoDV9ow7hqubWMW8q7hRCco7WdQhBoDZgGjO0QmvPq85G37P9rxJTl4NI0sPIYxiTpsgVBl6zhBcqPUF2MSBGt3Ec3qHiQFOQUidzJUyRyikSCkCWS0vfpJDFuBjT_uv5mUABfjwAsiz45jDLp4k8x0UXUWZrg_ivx5QWD7p13WvWPeMC0C2P0xUVJZWIS5N10F9NZUN4AtKJtfgM807dw</recordid><startdate>20151201</startdate><enddate>20151201</enddate><creator>Yoshida, Tatsuya</creator><creator>Yoh, Kiyotaka</creator><creator>Niho, Seiji</creator><creator>Umemura, Shigeki</creator><creator>Matsumoto, Shingo</creator><creator>Ohmatsu, Hironobu</creator><creator>Ohe, Yuichiro</creator><creator>Goto, Koichi</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20151201</creationdate><title>RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation</title><author>Yoshida, Tatsuya ; Yoh, Kiyotaka ; Niho, Seiji ; Umemura, Shigeki ; Matsumoto, Shingo ; Ohmatsu, Hironobu ; Ohe, Yuichiro ; Goto, Koichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-59035691d0bdcf56d2f9ab54cd25a65ff25f15849955eff8ae09efd0d30df8e03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Carcinoma, Non-Small-Cell Lung - diagnosis</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Disease Progression</topic><topic>EGFR tyrosine kinase inhibitors</topic><topic>Epidermal growth factor receptor mutation</topic><topic>Exons</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Lung Neoplasms - diagnosis</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - mortality</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Neoplasm Staging</topic><topic>Non-small cell lung cancer</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Pulmonary/Respiratory</topic><topic>Quinazolines - therapeutic use</topic><topic>Receptor, Epidermal Growth Factor - antagonists & inhibitors</topic><topic>Receptor, Epidermal Growth Factor - genetics</topic><topic>Response Evaluation Criteria in Solid Tumors</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoshida, Tatsuya</creatorcontrib><creatorcontrib>Yoh, Kiyotaka</creatorcontrib><creatorcontrib>Niho, Seiji</creatorcontrib><creatorcontrib>Umemura, Shigeki</creatorcontrib><creatorcontrib>Matsumoto, Shingo</creatorcontrib><creatorcontrib>Ohmatsu, Hironobu</creatorcontrib><creatorcontrib>Ohe, Yuichiro</creatorcontrib><creatorcontrib>Goto, Koichi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoshida, Tatsuya</au><au>Yoh, Kiyotaka</au><au>Niho, Seiji</au><au>Umemura, Shigeki</au><au>Matsumoto, Shingo</au><au>Ohmatsu, Hironobu</au><au>Ohe, Yuichiro</au><au>Goto, Koichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation</atitle><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle><addtitle>Lung Cancer</addtitle><date>2015-12-01</date><risdate>2015</risdate><volume>90</volume><issue>3</issue><spage>477</spage><epage>483</epage><pages>477-483</pages><issn>0169-5002</issn><eissn>1872-8332</eissn><abstract>Highlights • Progression patterns at the RECIST-PD during treatment with EGFR-TKIs were clinically heterogeneous. • We evaluated the association between progression patterns and clinical outcome after treatment. • Progression patterns at the RECIST-PD during EGFR-TKI treatment might be associated with clinical outcome after treatment failure.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>26604031</pmid><doi>10.1016/j.lungcan.2015.09.025</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0169-5002 |
| ispartof | Lung cancer (Amsterdam, Netherlands), 2015-12, Vol.90 (3), p.477-483 |
| issn | 0169-5002 1872-8332 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1760917235 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult Aged Aged, 80 and over Carcinoma, Non-Small-Cell Lung - diagnosis Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Disease Progression EGFR tyrosine kinase inhibitors Epidermal growth factor receptor mutation Exons Female Hematology, Oncology and Palliative Medicine Humans Kaplan-Meier Estimate Lung Neoplasms - diagnosis Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - mortality Male Middle Aged Mutation Neoplasm Staging Non-small cell lung cancer Protein Kinase Inhibitors - therapeutic use Pulmonary/Respiratory Quinazolines - therapeutic use Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - genetics Response Evaluation Criteria in Solid Tumors Retrospective Studies Treatment Outcome |
| title | RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T19%3A14%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=RECIST%20progression%20patterns%20during%20EGFR%20tyrosine%20kinase%20inhibitor%20treatment%20of%20advanced%20non-small%20cell%20lung%20cancer%20patients%20harboring%20an%20EGFR%20mutation&rft.jtitle=Lung%20cancer%20(Amsterdam,%20Netherlands)&rft.au=Yoshida,%20Tatsuya&rft.date=2015-12-01&rft.volume=90&rft.issue=3&rft.spage=477&rft.epage=483&rft.pages=477-483&rft.issn=0169-5002&rft.eissn=1872-8332&rft_id=info:doi/10.1016/j.lungcan.2015.09.025&rft_dat=%3Cproquest_cross%3E1760917235%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1760917235&rft_id=info:pmid/26604031&rft_els_id=S0169500215300696&rfr_iscdi=true |